Danshenxinkun A, Danshenxinkun B and Neocryptotanshinone may intervene thrombotic diseases by adjusting the targets mainly involved in pathways of endocrine system, signal transduction, signaling molecules and interaction, cell motility, environmental adaptation and nervous system.

PGD2-IN-1 是 DP 受体拮抗剂, 来自专利 WO 2006044732 A2，化合物实例 15 (d)，IC50 值为 0.3 nM。

Senkyunolide A 是从Ligusticum chuanxiong Hort 中分离得到的，具有细胞保护和抗增殖活性。抗肿瘤活性。